Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Griseofulvin (microsize)
Overview
What is Griseofulviin (microsize)?
Griseofulvin is an antibiotic derived from a species of Each 5 mL of Griseofulvin Oral Suspension USP contains 125 mg of griseofulvin microsize and also contains alcohol 0.2%, artificial orange vanilla flavor, docusate sodium, FD&C Red No. 40, FD&C Yellow No. 6, magnesium aluminium silicate, menthol, methylparaben, propylene glycol, propylparaben, saccharin sodium, simethicone emulsion, sodium alginate, sucrose, and purified water.
What does Griseofulviin (microsize) look like?
What are the available doses of Griseofulviin (microsize)?
Sorry No records found.
What should I talk to my health care provider before I take Griseofulviin (microsize)?
Sorry No records found
How should I use Griseofulviin (microsize)?
Major indications for Griseofulvin Oral Suspension are:
Griseofulvin inhibits the growth of those genera of fungi that commonly cause ringworm infections of the hair, skin, and nails, such as:
Note:
It is effective in:
Accurate diagnosis of the infecting organism is essential. Identification should be made either by direct microscopic examination of a mounting of infected tissue in a solution of potassium hydroxide or by culture on an appropriate medium.
Medication must be continued until the infecting organism is completely eradicated as indicated by appropriate clinical or laboratory examination. Representative treatment periods are tinea capitis, 4 to 6 weeks; tinea corporis, 2 to 4 weeks; tinea pedis, 4 to 8 weeks; tinea unguium--depending on rate of growth--fingernails, at least 4 months; toenails, at least 6 months.
General measures in regard to hygiene should be observed to control sources of infection or reinfection. Concomitant use of appropriate topical agents is usually required, particularly in treatment of tinea pedis since in some forms of athlete's foot, yeasts and bacteria may be involved. Griseofulvin will not eradicate the bacterial or monilial infection.
Adults:
For those fungus infections more difficult to eradicate such as tinea pedis and tinea unguium, a daily dose of 1 gram is recommended.
Children:
What interacts with Griseofulviin (microsize)?
Sorry No Records found
What are the warnings of Griseofulviin (microsize)?
Sorry No Records found
What are the precautions of Griseofulviin (microsize)?
Sorry No Records found
What are the side effects of Griseofulviin (microsize)?
Sorry No records found
What should I look out for while using Griseofulviin (microsize)?
This drug is contraindicated in patients with porphyria, hepatocellular failure, and in individuals with a history of hypersensitivity to griseofulvin.
Two cases of conjoined twins have been reported in patients taking griseofulvin during the first trimester of pregnancy. Griseofulvin should not be prescribed to pregnant patients.
Prophylactic Usage:
Chronic feeding of griseofulvin, at levels ranging from 0.5-2.5% of the diet, resulted in the development of liver tumors in several strains of mice, particularly in males. Smaller particle sizes result in an enhanced effect. Lower oral dosage levels have not been tested. Subcutaneous administration of relatively small doses of griseofulvin once a week during the first three weeks of life has also been reported to induce hepatomata in mice. Although studies in other animal species have not yielded evidence of tumorigenicity, these studies were not of adequate design to form a basis for conclusions in this regard.
In subacute toxicity studies, orally administered griseofulvin produced hepatocellular necrosis in mice, but this has not been seen in other species. Disturbances in porphyrin metabolism have been reported in griseofulvin-treated laboratory animals. Griseofulvin has been reported to have a colchicine-like effect on mitosis and cocarcinogenicity with methylcholanthrene in cutaneous tumor induction in laboratory animals.
Reports of animal studies in the Soviet literature state that a griseofulvin preparation was found to be embryotoxic and teratogenic on oral administration to pregnant Wistar rats. Rat reproduction studies done in the United States and Great Britain have been inconclusive in this regard, and additional animal reproduction studies are underway. Pups with abnormalities have been reported in the litters of a few bitches treated with griseofulvin.
Suppression of spermatogenesis has been reported to occur in rats but investigation in man failed to confirm this.
What might happen if I take too much Griseofulviin (microsize)?
Sorry No Records found
How should I store and handle Griseofulviin (microsize)?
Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature]. Keep tightly closed (protect from moisture). Protect from light.Griseofulvin Oral Suspension USP 125 mg per 5 mL is an orange-vanilla flavored suspension available in bottles of 4 fl oz (120 mL).Dispense Griseofulvin Oral Suspension in a tight, light-resistant container as defined in the USP.Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].Manufactured by:Actavis Mid Atlantic LLC1877 Kawai RoadLincolnton, NC 28092 USAForm No. 0013Rev. 7/07VC2965Repackaged by:Rebel Distributors Corp.Thousand Oaks, CA 91320Griseofulvin Oral Suspension USP 125 mg per 5 mL is an orange-vanilla flavored suspension available in bottles of 4 fl oz (120 mL).Dispense Griseofulvin Oral Suspension in a tight, light-resistant container as defined in the USP.Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].Manufactured by:Actavis Mid Atlantic LLC1877 Kawai RoadLincolnton, NC 28092 USAForm No. 0013Rev. 7/07VC2965Repackaged by:Rebel Distributors Corp.Thousand Oaks, CA 91320Griseofulvin Oral Suspension USP 125 mg per 5 mL is an orange-vanilla flavored suspension available in bottles of 4 fl oz (120 mL).Dispense Griseofulvin Oral Suspension in a tight, light-resistant container as defined in the USP.Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].Manufactured by:Actavis Mid Atlantic LLC1877 Kawai RoadLincolnton, NC 28092 USAForm No. 0013Rev. 7/07VC2965Repackaged by:Rebel Distributors Corp.Thousand Oaks, CA 91320Griseofulvin Oral Suspension USP 125 mg per 5 mL is an orange-vanilla flavored suspension available in bottles of 4 fl oz (120 mL).Dispense Griseofulvin Oral Suspension in a tight, light-resistant container as defined in the USP.Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].Manufactured by:Actavis Mid Atlantic LLC1877 Kawai RoadLincolnton, NC 28092 USAForm No. 0013Rev. 7/07VC2965Repackaged by:Rebel Distributors Corp.Thousand Oaks, CA 91320Griseofulvin Oral Suspension USP 125 mg per 5 mL is an orange-vanilla flavored suspension available in bottles of 4 fl oz (120 mL).Dispense Griseofulvin Oral Suspension in a tight, light-resistant container as defined in the USP.Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].Manufactured by:Actavis Mid Atlantic LLC1877 Kawai RoadLincolnton, NC 28092 USAForm No. 0013Rev. 7/07VC2965Repackaged by:Rebel Distributors Corp.Thousand Oaks, CA 91320Griseofulvin Oral Suspension USP 125 mg per 5 mL is an orange-vanilla flavored suspension available in bottles of 4 fl oz (120 mL).Dispense Griseofulvin Oral Suspension in a tight, light-resistant container as defined in the USP.Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].Manufactured by:Actavis Mid Atlantic LLC1877 Kawai RoadLincolnton, NC 28092 USAForm No. 0013Rev. 7/07VC2965Repackaged by:Rebel Distributors Corp.Thousand Oaks, CA 91320Griseofulvin Oral Suspension USP 125 mg per 5 mL is an orange-vanilla flavored suspension available in bottles of 4 fl oz (120 mL).Dispense Griseofulvin Oral Suspension in a tight, light-resistant container as defined in the USP.Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].Manufactured by:Actavis Mid Atlantic LLC1877 Kawai RoadLincolnton, NC 28092 USAForm No. 0013Rev. 7/07VC2965Repackaged by:Rebel Distributors Corp.Thousand Oaks, CA 91320Griseofulvin Oral Suspension USP 125 mg per 5 mL is an orange-vanilla flavored suspension available in bottles of 4 fl oz (120 mL).Dispense Griseofulvin Oral Suspension in a tight, light-resistant container as defined in the USP.Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].Manufactured by:Actavis Mid Atlantic LLC1877 Kawai RoadLincolnton, NC 28092 USAForm No. 0013Rev. 7/07VC2965Repackaged by:Rebel Distributors Corp.Thousand Oaks, CA 91320Griseofulvin Oral Suspension USP 125 mg per 5 mL is an orange-vanilla flavored suspension available in bottles of 4 fl oz (120 mL).Dispense Griseofulvin Oral Suspension in a tight, light-resistant container as defined in the USP.Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].Manufactured by:Actavis Mid Atlantic LLC1877 Kawai RoadLincolnton, NC 28092 USAForm No. 0013Rev. 7/07VC2965Repackaged by:Rebel Distributors Corp.Thousand Oaks, CA 91320Griseofulvin Oral Suspension USP 125 mg per 5 mL is an orange-vanilla flavored suspension available in bottles of 4 fl oz (120 mL).Dispense Griseofulvin Oral Suspension in a tight, light-resistant container as defined in the USP.Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].Manufactured by:Actavis Mid Atlantic LLC1877 Kawai RoadLincolnton, NC 28092 USAForm No. 0013Rev. 7/07VC2965Repackaged by:Rebel Distributors Corp.Thousand Oaks, CA 91320Griseofulvin Oral Suspension USP 125 mg per 5 mL is an orange-vanilla flavored suspension available in bottles of 4 fl oz (120 mL).Dispense Griseofulvin Oral Suspension in a tight, light-resistant container as defined in the USP.Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].Manufactured by:Actavis Mid Atlantic LLC1877 Kawai RoadLincolnton, NC 28092 USAForm No. 0013Rev. 7/07VC2965Repackaged by:Rebel Distributors Corp.Thousand Oaks, CA 91320Griseofulvin Oral Suspension USP 125 mg per 5 mL is an orange-vanilla flavored suspension available in bottles of 4 fl oz (120 mL).Dispense Griseofulvin Oral Suspension in a tight, light-resistant container as defined in the USP.Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].Manufactured by:Actavis Mid Atlantic LLC1877 Kawai RoadLincolnton, NC 28092 USAForm No. 0013Rev. 7/07VC2965Repackaged by:Rebel Distributors Corp.Thousand Oaks, CA 91320Griseofulvin Oral Suspension USP 125 mg per 5 mL is an orange-vanilla flavored suspension available in bottles of 4 fl oz (120 mL).Dispense Griseofulvin Oral Suspension in a tight, light-resistant container as defined in the USP.Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].Manufactured by:Actavis Mid Atlantic LLC1877 Kawai RoadLincolnton, NC 28092 USAForm No. 0013Rev. 7/07VC2965Repackaged by:Rebel Distributors Corp.Thousand Oaks, CA 91320
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Griseofulvin acts systemically to inhibit the growth of and genera of fungi. Fungistatic amounts are deposited in the keratin, which is gradually exfoliated and replaced by noninfected tissue.
Griseofulvin absorption from the gastrointestinal tract varies considerably among individuals, mainly because of insolubility of the drug in aqueous media of the upper G.I. tract. The peak serum level found in fasting adults given 0.5 gm occurs at about four hours and ranges between 0.5 and 2.0 mcg/mL.
It should be noted that some individuals are consistently "poor absorbers" and tend to attain lower blood levels at all times. This may explain unsatisfactory therapeutic results in some patients. Better blood levels can probably be attained in most patients if griseofulvin is administered after a meal with a high fat content.
Non-Clinical Toxicology
This drug is contraindicated in patients with porphyria, hepatocellular failure, and in individuals with a history of hypersensitivity to griseofulvin.Two cases of conjoined twins have been reported in patients taking griseofulvin during the first trimester of pregnancy. Griseofulvin should not be prescribed to pregnant patients.
Prophylactic Usage:
Chronic feeding of griseofulvin, at levels ranging from 0.5-2.5% of the diet, resulted in the development of liver tumors in several strains of mice, particularly in males. Smaller particle sizes result in an enhanced effect. Lower oral dosage levels have not been tested. Subcutaneous administration of relatively small doses of griseofulvin once a week during the first three weeks of life has also been reported to induce hepatomata in mice. Although studies in other animal species have not yielded evidence of tumorigenicity, these studies were not of adequate design to form a basis for conclusions in this regard.
In subacute toxicity studies, orally administered griseofulvin produced hepatocellular necrosis in mice, but this has not been seen in other species. Disturbances in porphyrin metabolism have been reported in griseofulvin-treated laboratory animals. Griseofulvin has been reported to have a colchicine-like effect on mitosis and cocarcinogenicity with methylcholanthrene in cutaneous tumor induction in laboratory animals.
Reports of animal studies in the Soviet literature state that a griseofulvin preparation was found to be embryotoxic and teratogenic on oral administration to pregnant Wistar rats. Rat reproduction studies done in the United States and Great Britain have been inconclusive in this regard, and additional animal reproduction studies are underway. Pups with abnormalities have been reported in the litters of a few bitches treated with griseofulvin.
Suppression of spermatogenesis has been reported to occur in rats but investigation in man failed to confirm this.
Alcohol, ethyl: Hepatotoxicity has occurred in chronic alcoholics following various dose levels (moderate to excessive) of acetaminophen.
Anticholinergics: The onset of acetaminophen effect may be delayed or decreased slightly, but the ultimate pharmacological effect is not significantly affected by anticholinergics.
Oral Contraceptives: Increase in glucuronidation resulting in increased plasma clearance and a decreased half-life of acetaminophen.
Charcoal (activated): Reduces acetaminophen absorption when administered as soon as possible after overdose.
Beta Blockers (Propanolol): Propanolol appears to inhibit the enzyme systems responsible for the glucuronidation and oxidation of acetaminophen Therefore, the pharmacologic effects of acetaminophen may be increased.
Loop diuretics: The effects of the loop diuretic may be decreased because acetaminophen may decrease renal prostaglandin excretion and decrease plasma renin activity.
Lamotrigine: Serum lamotrigine concentrations may be reduced, producing a decrease in therapeutic effects.
Probenecid: Probenecid may increase the therapeutic effectiveness of acetaminophen slightly.
Zidovudine: The pharmacologic effects of zidovudine may be decreased because of enhanced non-hepatic or renal clearance of zidovudine.
Patients on prolonged therapy with any potent medication should be under close observation. Periodic monitoring of organ system function, including renal, hepatic and hemopoietic, should be done.
Since griseofulvin is derived from species of penicillin, the possibility of cross sensitivity with penicillin exists; however, known penicillin-sensitive patients have been treated without difficulty.
Since a photosensitivity reaction is occasionally associated with griseofulvin therapy, patients should be warned to avoid exposure to intense natural or artificial sunlight. Should a photosensitivity reaction occur, lupus erythematosus may be aggravated.
When adverse reactions occur, they are most commonly of the hypersensitivity type such as skin rashes, urticaria and rarely, angioneurotic edema or erythema multiforme-like drug reaction, and may necessitate withdrawal of therapy and appropriate countermeasures. Paresthesias of the hands and feet have been reported rarely after extended therapy. Other side effects reported occasionally are oral thrush, nausea, vomiting, epigastric distress, diarrhea, headache, fatigue, dizziness, insomnia, mental confusion and impairment of performance of routine activities.
Proteinuria and leukopenia have been reported rarely. Administration of the drug should be discontinued if granulocytopenia occurs.
When rare, serious reactions occur with griseofulvin, they are usually associated with high dosages, long periods of therapy, or both.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
514Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).